Abstracts

1042 – HIV-Specific T-Cell Dynamics in Acute-Treated, Chronic-Treated, and Elite Controller People With HIV

Background Early initiation of ART can preserve immune function and is associated with increased incidence of post-treatment control of HIV, yet differences in HIV-specific immune responses between people with HIV (PWH) who initiated ART during acute vs. chronic infection are poorly defined. The extent to which immune responses in early- and late-treated PWH differ from…

478 – Evaluation of the PHH-1V COVID-19 Vaccine-Induced T-Cell Responses in Adolescents: HIPRA-HH-3 Study

Background PHH-1V (BIMERVAX®) is an adjuvanted recombinant protein vaccine based on a dimeric RBD of the Alpha/Beta SARS-CoV-2 variants. In march 2023 PHH-1V received full marketing approval by EMA (European Medicines Agency) to be used as a heterologous booster for preventing coronavirus disease 2019 (COVID-19) in people aged 16 and older. The HH-3 study (Phase IIb, Open-label, Multi-center, Non-Inferiority, NCT06234956)…

438 – Evolution and Durability of Mpox-Specific Antibodies Among Vaccinated or Infected Individuals

Background While two-dose vaccination using modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine has been shown to be effective in preventing Mpox among at-risk populations, data on the short-term durability of serological responses are scarce. Methods This prospective study enrolled participants planning to undergo 2-dose MVA-BN vaccination or having natural infection to investigate the serological responses after…

414 – Structural Insight into the High- and Low-Affinity Alleles of Human and Macaque FcγRIIA (CD32A)

Background Rhesus macaques (RM), Macaca mulatta, are one of the main nonhuman primate models for the testing of vaccines and antibody-based therapeutics. Macaques, like humans, have high and a low affinity alleles of FcγRIIA (CD32A) which is expressed on macrophages, dendritic cells and other antigen presenting cells. The polymorphism in FcγRIIA potentially influences the ‘vaccinal…

561 – In-Depth Evaluation of the Intact Proviral DNA Assay for the Quantification of HIV-1 Reservoir

Background Accurate quantification of the HIV-1 reservoir is critical in understanding HIV-1 persistence and evaluating cure strategies. The Intact Proviral DNA Assay (IPDA), a droplet digital PCR assay that simultaneously targets the HIV-1 packaging signal (psi) and env, is widely used to quantify the intact or rebound-competent reservoir but has not been thoroughly evaluated. We…

479 – T-Cell Immunity of PHH-1V COVID-19 Vaccine in PWH and Adults With Immunosuppressive Conditions

Background Protective vaccines became an urgent need during the COVID-19 pandemic. People with immunodeficiencies particularly benefit from COVID-19 vaccination. PHH-1V (BIMERVAX®) is an authorized and adjuvanted recombinant vaccine based on a dimeric RBD of Alpha/Beta SARS-CoV-2 variants. HH-4 was a Phase IIb/III, open-label, single-arm, multi-center study (NCT05303402) to evaluate the humoral and cellular immune response…

456 – IFI16 Controls PVR and Gal-9 Expression and Its Targeting Improves Immunotherapy Against HIV-1

Background Stimulation of HIV-1 specific CD8+ T cells with Monocyte-derived dendritic-cells (MDDC) in an attractive immunotherapy strategy against HIV-1. However, chronic inflammation in People with HIV (PWH) has been linked to low CD4/CD8 T cell ratios, activation of the inflammasome and may affect the expression of checkpoint ligands in Mo, limiting efficacy of MDDCs. Here,…

476 – The XBB.1.5 mRNA Booster Vaccine Does Not Significantly Increase XBB.1.5 Mono-Reactive T Cells

Background SARS-CoV-2 variants such as XBB.1.5 and BA.2.86 have emerged with mutations that allow them to evade neutralizing antibodies elicited by ancestral and bivalent mRNA vaccines. Despite the introduction of the XBB.1.5 monovalent booster to improve T cell immunity, it remains unclear whether this vaccine induces stronger XBB.1.5-specific T cell responses compared to the ancestral/BA.5…

480 – Torque Teno Virus: A Predictive Biomarker for SARS-CoV-2 Vaccine Response in Immunosuppressed People

Background Solid organ transplant recipients (SOTRs) are highly susceptible to severe COVID-19 due to chronic immunosuppressive treatment aimed at preventing organ rejection, along with associated comorbidities. Their vaccine responses are often diminished compared to the general population. Identifying a biomarker that reflects immune status and predicts vaccination response is crucial for optimizing vaccination strategies. Torque…